A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer.
about
Chemodiversity in freshwater and terrestrial cyanobacteria - a source for drug discoveryStabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Microtubule-binding agents: a dynamic field of cancer therapeutics.New peptides isolated from Lyngbya species: a reviewMarine pharmacology in 2005-2006: antitumour and cytotoxic compounds.Uncovering Potential Applications of Cyanobacteria and Algal Metabolites in Biology, Agriculture and Medicine: Current Status and Future Prospects.A phase 2 trial of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: MC0261Overcoming platinum resistance in ovarian carcinoma.Biological targets and mechanisms of action of natural products from marine cyanobacteria.Marine Peptides: Bioactivities and ApplicationsDrug target interaction of tubulin-binding drugs in cancer therapy.Frontiers and opportunities in chemoenzymatic synthesis.Cyanobacteria: potential candidates for drug discovery.Recent approaches for the synthesis of modified cryptophycins.Recent developments in therapeutic applications of Cyanobacteria.Tubulin Inhibitor-Based Antibody-Drug Conjugates for Cancer Therapy.Early investigational tubulin inhibitors as novel cancer therapeutics.Cyanobacteria from terrestrial and marine sources contain apoptogens able to overcome chemoresistance in acute myeloid leukemia cells.Cylindrocyclophanes with proteasome inhibitory activity from the Cyanobacterium Nostoc sp.Cryptophycins: cytotoxic cyclodepsipeptides with potential for tumor targeting.Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides.Novel unit B cryptophycin analogues as payloads for targeted therapy.Epothilones and new analogues of the microtubule modulators in taxane-resistant disease
P2860
Q24623272-6123D4A2-2DDE-4C18-9199-D9A86B9F7BB1Q26781365-8DBCF76F-3FA2-45DB-A99D-AA8B48D97D1CQ27690249-71D9BA6E-F963-44AD-A6C6-E4F4916CFAEEQ28750378-6F013DEF-E77C-4DDB-94F7-6617F065E5E1Q33359943-7539C108-B97F-4A5E-B799-494859EA3F53Q33600275-D8A798B7-5C8C-4ED9-A695-A7D0C0C479D6Q34023223-68848159-92AC-4D2F-8AD8-8B3D8B1DDACAQ34233273-FA677320-159C-4D69-B032-6CF1E8C8F4B5Q35130835-9623319E-77C5-4513-803A-08BAB05BC703Q35890691-67875683-0D7F-4AF7-85AE-6BEE5C23F118Q36636645-A760C2E4-06F3-47F4-91F2-829D72A5C44FQ37794952-2727328D-0D16-4238-A77F-672F4586188EQ38093448-01984C82-28DB-444F-A41E-B5334F70A556Q38111652-BF242FFF-B528-4821-B8B0-01C063C12762Q38335345-5A169CB9-85BA-4263-8E11-156D48344860Q38648690-46CBCB98-F318-447C-B00F-FE1F791B3C2FQ38836161-3D40A799-0147-4C86-A3D7-FD155B5E1D1EQ39007306-539AF970-26EC-46DE-A7B7-6B8F7E78E9D6Q42026439-9DEE7558-4EEC-467C-AE21-3D791AFFDD81Q48202119-7D35BF75-F13D-4E30-A34B-5E9211A543A6Q52646693-3AEE85DE-BCCA-4E8A-ADD3-DD25663394DBQ55415772-F53D8621-8FCA-4FD9-BB01-DEF726BC0E41Q57244875-347F5B98-9D2F-401D-AA10-E80A65AA7742
P2860
A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A multicenter phase II study o ...... inum-resistant ovarian cancer.
@ast
A multicenter phase II study o ...... inum-resistant ovarian cancer.
@en
type
label
A multicenter phase II study o ...... inum-resistant ovarian cancer.
@ast
A multicenter phase II study o ...... inum-resistant ovarian cancer.
@en
prefLabel
A multicenter phase II study o ...... inum-resistant ovarian cancer.
@ast
A multicenter phase II study o ...... inum-resistant ovarian cancer.
@en
P2093
P1476
A multicenter phase II study o ...... tinum-resistant ovarian cancer
@en
P2093
G D'Agostino
J del Campo
M A Izquierdo
P356
10.1111/J.1525-1438.2006.00276.X
P577
2006-01-01T00:00:00Z